This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

Extract from the above information

It is a selective β2 receptor agonist, which has a strong and lasting effect in relaxing bronchial smooth muscles. It can enhance ciliary movement, dissolve mucus and promote sputum discharge. However, it has little effect on the cardiovascular system.

It is a selective β2 receptor agonist, which has a strong and lasting effect in relaxing bronchial smooth muscles. It can enhance ciliary movement, dissolve mucus and promote sputum discharge. However, it has little effect on the cardiovascular system.

It is a selective β2 receptor agonist, which has a strong and lasting effect in relaxing bronchial smooth muscles. It can enhance ciliary movement, dissolve mucus and promote sputum discharge. However, it has little effect on the cardiovascular system.

It has a strong and lasting effect in relaxing bronchial smooth muscles. It can enhance ciliary movement, dissolve mucus and promote sputum discharge. However, it has little effect on the cardiovascular system.

Restores the imbalance between the excitation and inhibition processes of the cerebral cortex, and has central inhibitory effects such as sedation, hypnosis and analgesia

This product is a thromboxane (TX) synthase inhibitor, which can inhibit the generation of thromboxane A2 (TXA2) from prostaglandin H2 (PGH2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance between TXA2 and prostaglandin PGI2. Theoretically, it can inhibit platelet aggregation and vasodilation. This product can improve movement disorders in the acute stage of cerebral thrombosis, improve circulatory disorders in the acute stage of cerebral ischemia, and improve abnormal energy metabolism during cerebral ischemia. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels, increase the ratio of 6-Keto-PGF1a/TXB2, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery occlusion in rats. The half-maximal inhibitory concentration IC50 of this product for human platelet aggregation is low, at 4nM. Experiments using autologous blood injected into the subarachnoid hemorrhage model showed that continuous intravenous injection of this product has the effects of inhibiting blood TXB2 concentration and cerebral vasoconstriction.